AGTR1 and neuromuscular disease: It has been shown that TGF-β signal inhibition using a TGF-β-neutralizing antibody or the angiotensin II type 1 receptor blocker losartan (an) reduces fibrosis levels and restores muscle architecture and function in two neuromuscular disease mouse models: the mdx mice and the fibrillin-1-deficient mice (Fbn1C1039G/+, Marfan Syndrome) [26].